First I would like to make it clear, because I think there's been confusion off and on, but we have not rejected the proposal for a TRIPS waiver. Obviously a significant number of WTO members support a TRIPS waiver, and the proposal was put forward by India and South Africa, as you know, but also a number of members are opposing the waiver proposal outright, so there's no consensus on a way forward. That leaves us effectively stuck, at least for the moment.
Therefore, we have been trying to see if we can find a way for Canada to dig a little deeper into some of the issues and if we can try to find solutions that could be accepted more broadly. That's the tack we've been taking. We very much want to find a solution.
Most recently we've started to support what is clearly a parallel track of the WTO director general's so-called “third way effort”, which involves a dialogue directly with the pharmaceutical industry, looking at where we have production challenges and how those can be fixed, and where we have distribution challenges and how those can be fixed.
The problem is very clear. How we can best address it is an ongoing challenge. We're certainly optimistic about this third way that the WTO director general is pursuing. It doesn't mean we drop the issue of the TRIPS waiver. We continue to work on that as well. It's a matter of trying to make sure we can solve this issue as quickly as we possibly can. We don't want to get into a position where we're going to get stuck and not make progress.